Bio-Techne Corporation
TECH NASDAQHealthcare ★★★★★Latest Earnings FY2026 Q4
Date
Aug 12, 2026
ET
EPS Est.
0.52
EPS Actual
0.52
Revenue Est.
$314.6M
Revenue Actual
$321.2M
Next Earnings Report
Date
Nov 4, 2026 · Wed
Time
Pre-market
Fiscal Period
FY2027 Q1
EPS Est.
0.46
Revenue Est.
$292.1M
Company Overview
Bio-Techne Corporation (ticker TECH) is listed on NASDAQ with a market cap of about $11.32B. Its next earnings report (FY2027 Q1) is expected on Nov 4, 2026 (ET), Pre-market, with consensus EPS of 0.46. In the last 15 reported quarters, EPS beat consensus estimates 7 times.
Actual EPS TrendRecently15Term · Feb 2, 2023 → FY2026 Q4
Feb 2, 2023Range: 0.40 ~ 0.56FY2026 Q4
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 12, 2026 | FY2026 Q4 | 0.52 | 0.52 | $314.6M | $321.2M |
| May 6, 2026 | -- | 0.55 | 0.53 | $316.1M | $311.4M |
| Feb 4, 2026 | -- | 0.43 | 0.46 | $290.5M | $295.9M |
| Nov 5, 2025 | -- | 0.42 | 0.42 | $291.3M | $286.6M |
| Aug 6, 2025 | -- | 0.50 | 0.53 | $294.6M | $317M |
| May 7, 2025 | -- | 0.51 | 0.56 | $325.5M | $316.2M |
| Feb 5, 2025 | -- | 0.39 | 0.42 | $317.5M | $297M |
| Oct 30, 2024 | -- | 0.38 | 0.42 | $280.3M | $289.5M |
| Aug 7, 2024 | -- | 0.49 | 0.49 | $306.5M | $306.1M |
| May 1, 2024 | -- | 0.45 | 0.48 | $306.1M | $303.4M |
| Feb 1, 2024 | -- | 0.41 | 0.40 | $277.8M | $272.6M |
| Oct 31, 2023 | -- | 0.44 | 0.41 | $291.4M | $276.9M |
| Aug 8, 2023 | -- | 0.55 | 0.55 | $307.3M | $301.3M |
| May 3, 2023 | -- | 0.53 | 0.53 | $296.7M | $294.1M |
| Feb 2, 2023 | -- | 0.49 | 0.47 | $288.8M | $271.6M |
Original Filings (SEC)
8-K2026-08-12 ↗
8-K2026-06-26 ↗
8-K2026-06-25 ↗
10-Q2026-05-06 ↗
8-K2026-05-06 ↗
8-K2026-02-11 ↗
10-Q2026-02-04 ↗
8-K2026-02-04 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
